{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:57:31Z","timestamp":1793717851652,"version":"4.6.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T00:00:00Z","timestamp":1621641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Exploratory Research in Clinical and Social Pharmacy"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.rcsop.2021.100029","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T14:48:24Z","timestamp":1622818104000},"page":"100029","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"special_numbering":"C","title":["A systematic literature review of patient perspectives of barriers and facilitators to access, adherence, stigma, and persistence to treatment for substance use disorder"],"prefix":"10.1016","volume":"2","author":[{"given":"Alina","family":"Cernasev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Hohmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey","family":"Frederick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary","family":"Jasmin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Gatwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rcsop.2021.100029_bb0005","series-title":"Understanding the epidemic","author":"Center for Disease Control","year":"2020"},{"issue":"2","key":"10.1016\/j.rcsop.2021.100029_bb0010","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.juro.2010.09.088","article-title":"Overprescription of postoperative narcotics: a look at postoperative pain medication delivery, consumption and disposal in urological practice","volume":"185","author":"Bates","year":"2011","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.rcsop.2021.100029_bb0015","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10612-010-9113-9","article-title":"OxyContin and a regulation deficiency of the pharmaceutical industry: rethinking state-corporate crime","volume":"19","author":"Griffin","year":"2011","journal-title":"Crit Criminol"},{"issue":"3","key":"10.1016\/j.rcsop.2021.100029_bb0020","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMsa1406143","article-title":"Trends in opioid analgesic abuse and mortality in the United States","volume":"372","author":"Dart","year":"2015","journal-title":"New Engl J Med"},{"key":"10.1016\/j.rcsop.2021.100029_bb0025","article-title":"Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use","author":"National Academies of Sciences, Engineering, and Medicine","year":"2017"},{"issue":"4","key":"10.1016\/j.rcsop.2021.100029_bb0030","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/01.j.pain.0000460357.01998.f1","article-title":"Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis","volume":"156","author":"Vowles","year":"2015","journal-title":"Pain."},{"issue":"7","key":"10.1016\/j.rcsop.2021.100029_bb0035","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jamapsychiatry.2014.366","article-title":"The changing face of heroin use in the United States a retrospective analysis of the past 50 years","volume":"71","author":"Cicero","year":"2014","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1016\/j.rcsop.2021.100029_bb0040","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/ajt.13776","article-title":"Increases in drug and opioid overdose deaths - United States, 2000-2014","volume":"16","author":"Rudd","year":"2016","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.rcsop.2021.100029_bb0045","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.drugpo.2013.10.004","article-title":"\u201cEvery \u2018never\u2019 i ever said came true\u201d: transitions from opioid pills to heroin injecting","volume":"25","author":"Mars","year":"2014","journal-title":"Int J Drug Policy."},{"key":"10.1016\/j.rcsop.2021.100029_bb0050","series-title":"Opioid overdose crisis","author":"Abuse","year":"2020"},{"issue":"3","key":"10.1016\/j.rcsop.2021.100029_bb0055","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/PHH.0000000000000849","article-title":"Integrating public health and health care strategies to address the opioid epidemic: the Oregon health Authority\u2019s opioid initiative","volume":"25","author":"Hedberg","year":"2019","journal-title":"J Public Health Manag Pract"},{"key":"10.1016\/j.rcsop.2021.100029_bb0060","series-title":"Pain management and the opioid epidemic: balancing societal and individual benefits and risks of prescription opioid use","author":"National Academies of Sciences E, Medicine","year":"2017"},{"key":"10.1016\/j.rcsop.2021.100029_bb0065","series-title":"Life-saving naloxone from pharmacies","author":"Center for Disease Control L-snfp","year":"2020"},{"issue":"2","key":"10.1016\/j.rcsop.2021.100029_bb0070","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2105\/AJPH.2017.304187","article-title":"Opioid crisis: no easy fix to its social and economic determinants","volume":"108","author":"Dasgupta","year":"2018","journal-title":"Am J Public Health"},{"issue":"8","key":"10.1016\/j.rcsop.2021.100029_bb0075","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1377\/hlthaff.2010.0532","article-title":"The evidence Doesn\u2019t justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine","volume":"30","author":"Clark","year":"2011","journal-title":"Health Aff"},{"issue":"20","key":"10.1016\/j.rcsop.2021.100029_bb0080","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1001\/jama.1988.03410200081030","article-title":"Implications of methadone maintenance for theories of narcotic addiction","volume":"260","author":"Dole","year":"1988","journal-title":"JAMA."},{"issue":"2","key":"10.1016\/j.rcsop.2021.100029_bb0085","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/HRP.0000000000000075","article-title":"Medication-assisted treatment of opioid use disorder: review of the evidence and future directions","volume":"23","author":"Connery","year":"2015","journal-title":"Harv Rev Psychiatry"},{"issue":"7","key":"10.1016\/j.rcsop.2021.100029_bb0090","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/ajhp\/zxy089","article-title":"The opioid crisis: origins, trends, policies, and the roles of pharmacists","volume":"76","author":"Chisholm-Burns","year":"2019","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"10.1016\/j.rcsop.2021.100029_bb0095","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13722-019-0139-3","article-title":"Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence","volume":"14","author":"Godersky","year":"2019","journal-title":"Addict Sci Clin Pract"},{"issue":"2","key":"10.1016\/j.rcsop.2021.100029_bb0100","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/10826084.2017.1400068","article-title":"From narcotic to normalizer: the misperception of methadone treatment and the persistence of prejudice and bias","volume":"53","author":"Woods","year":"2018","journal-title":"Subst Use Misuse."},{"issue":"2","key":"10.1016\/j.rcsop.2021.100029_bb0105","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5055\/jom.2007.0045","article-title":"Psychological factors as predictors of opioid abuse and illicit drug use in chronic pain patients","volume":"3","author":"Manchikanti","year":"2007","journal-title":"J Opioid Manag"},{"issue":"14","key":"10.1016\/j.rcsop.2021.100029_bb0110","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1001\/jama.2014.2147","article-title":"Confronting the stigma of opioid use disorder\u2014and its treatment","volume":"311","author":"Olsen","year":"2014","journal-title":"JAMA."},{"key":"10.1016\/j.rcsop.2021.100029_bb0115","author":"United States Department of Health and Human Services"},{"key":"10.1016\/j.rcsop.2021.100029_bb0120","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.drugpo.2019.03.012","article-title":"Stigma and drug use settings as correlates of self-reported, non-fatal overdose among people who use drugs in Baltimore","volume":"68","author":"Latkin","year":"2019","journal-title":"Maryland Int J Drug Policy"},{"issue":"2\u20133","key":"10.1016\/j.rcsop.2021.100029_bb0125","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.drugalcdep.2006.10.014","article-title":"Stigma, discrimination and the health of illicit drug users","volume":"88","author":"Ahern","year":"2007","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.rcsop.2021.100029_bb0130","article-title":"\u201cDon\u2019t judge a book by its cover\u201d: a qualitative study of methadone Patients\u2019 experiences of stigma","volume":"11","author":"Julia","year":"2017","journal-title":"Subst Abuse"},{"key":"10.1016\/j.rcsop.2021.100029_bb0135","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.drugalcdep.2017.08.002","article-title":"Internalized stigma as an independent risk factor for substance use problems among primary care patients: rationale and preliminary support","volume":"180","author":"Kulesza","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.rcsop.2021.100029_bb0140","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1146\/annurev.soc.27.1.363","article-title":"Conceptualizing stigma","volume":"27","author":"Link","year":"2001","journal-title":"Annu Rev Sociol"},{"key":"10.1016\/j.rcsop.2021.100029_bb0145","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.drugalcdep.2018.04.012","article-title":"Exploring opioid use disorder, its impact, and treatment among individuals experiencing homelessness as part of a family","volume":"188","author":"Chatterjee","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"10.1016\/j.rcsop.2021.100029_bb0150","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.japh.2017.01.013","article-title":"Perpetuating stigma or reducing risk\u202f? Perspectives from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states","volume":"57","author":"Green","year":"2017","journal-title":"J Am Pharm Assoc"},{"issue":"1","key":"10.1016\/j.rcsop.2021.100029_bb0155","doi-asserted-by":"crossref","DOI":"10.1186\/s13722-019-0166-0","article-title":"Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail","volume":"14","author":"Velasquez","year":"2019","journal-title":"Addict Sci Clin Pract"},{"issue":"5","key":"10.1016\/j.rcsop.2021.100029_bb0160","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.contraception.2020.09.002","article-title":"\u201cIt\u2019s a very nuanced discussion with every woman\u201d: Health care providers\u2019 communication practices during contraceptive counseling for patients with substance use disorders","volume":"102","author":"Charron","year":"2020","journal-title":"Contraception."},{"key":"10.1016\/j.rcsop.2021.100029_bb0165","article-title":"Methadone maintenance at different dosages for opioid dependence","volume":"3","author":"Faggiano","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rcsop.2021.100029_bb0170","article-title":"Dihydrocodeine for detoxification and maintenance treatment in individuals with opiate use disorders","volume":"2","author":"Carney","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rcsop.2021.100029_bb0175","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rcsop.2021.100029_bb0180","first-page":"82","article-title":"Using meta-ethnography to synthesise qualitative research","volume":"75","author":"Campbell","year":"2006","journal-title":"Moving beyond effectiveness in evidence synthesis"},{"issue":"4","key":"10.1016\/j.rcsop.2021.100029_bb0185","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1258\/135581902320432732","article-title":"Using meta ethnography to synthesise qualitative research: a worked example","volume":"7","author":"Britten","year":"2002","journal-title":"J Health Serv Res Policy"},{"key":"10.1016\/j.rcsop.2021.100029_bb0190","series-title":"Balancing the strengths of systematic and narrative reviews","author":"Collins","year":"2005"},{"issue":"10","key":"10.1016\/j.rcsop.2021.100029_bb0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001895","article-title":"Using qualitative evidence in decision making for health and social interventions: an approach to assess confidence in findings from qualitative evidence syntheses (GRADE-CERQual)","volume":"12","author":"Lewin","year":"2015","journal-title":"PLoS Med"},{"key":"10.1016\/j.rcsop.2021.100029_bb0200","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.drugpo.2016.10.012","article-title":"\u201cNot human, dead already\u201d: perceptions and experiences of drug-related stigma among opioid-using young adults from the former Soviet Union living in the U.S","volume":"38","author":"Gunn","year":"2016","journal-title":"Int J Drug Policy."},{"key":"10.1016\/j.rcsop.2021.100029_bb0205","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jsat.2019.04.008","article-title":"Experiences of care among individuals with opioid use disorder-associated endocarditis and their healthcare providers: results from a qualitative study","volume":"102","author":"Bearnot","year":"2019","journal-title":"J Subst Abus Treat"},{"issue":"2","key":"10.1016\/j.rcsop.2021.100029_bb0210","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/10826084.2017.1385633","article-title":"At the expense of a life: race, class, and the meaning of buprenorphine in Pharmaceuticalized \u201ccare\u201d","volume":"53","author":"Hatcher","year":"2018","journal-title":"Subst Use Misuse."},{"issue":"1","key":"10.1016\/j.rcsop.2021.100029_bb0215","doi-asserted-by":"crossref","DOI":"10.1186\/s13011-016-0085-y","article-title":"Systemic and individual factors in the buprenorphine treatment-seeking process: A qualitative study","volume":"12","author":"Hewell","year":"2017","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"1","key":"10.1016\/j.rcsop.2021.100029_bb0220","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/10550887.2012.759860","article-title":"Suboxone misuse along the opiate maintenance treatment pathway","volume":"32","author":"Furst","year":"2013","journal-title":"J Addict Dis"},{"issue":"14","key":"10.1016\/j.rcsop.2021.100029_bb0225","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1080\/10826084.2019.1653324","article-title":"Patient barriers and facilitators to medications for opioid use disorder in primary care","volume":"54","author":"Tofighi","year":"2019","journal-title":"Subst Use Misuse."},{"issue":"5","key":"10.1016\/j.rcsop.2021.100029_bb0230","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/NNR.0000000000000298","article-title":"Opioid initiation to substance use treatment: \u201cthey Just Want to Feel Normal\u201d","volume":"67","author":"Wilson","year":"2018","journal-title":"Nurs Res"},{"issue":"2","key":"10.1016\/j.rcsop.2021.100029_bb0235","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/02791072.2011.587392","article-title":"Redefining retention: recovery from the patient\u2019s perspective","volume":"43","author":"Mitchell","year":"2011","journal-title":"J Psychoactive Drugs"},{"issue":"1","key":"10.1016\/j.rcsop.2021.100029_bb0240","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.drugpo.2008.07.004","article-title":"Why don\u2019t out-of-treatment individuals enter methadone treatment programmes?","volume":"21","author":"Peterson","year":"2010","journal-title":"Int J Drug Policy"},{"issue":"5","key":"10.1016\/j.rcsop.2021.100029_bb0245","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1080\/02791072.2014.921743","article-title":"Patient perspectives on buprenorphine\/naloxone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study","volume":"46","author":"Teruya","year":"2014","journal-title":"J Psychoactive Drugs"},{"issue":"5","key":"10.1016\/j.rcsop.2021.100029_bb0250","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1177\/1060028014523730","article-title":"Naloxone for opioid overdose prevention: pharmacists\u2019 role in community-based practice settings","volume":"48","author":"Bailey","year":"2014","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.rcsop.2021.100029_bb0255","article-title":"Using the theory of planned behavior to investigate community pharmacists\u2019 beliefs regarding engaging patients about prescription drug misuse","author":"Fleming","year":"2018","journal-title":"Res Social Adm Pharm."},{"key":"10.1016\/j.rcsop.2021.100029_bb0260","article-title":"Physician-pharmacist collaboration on chronic non-cancer pain management during the opioid crisis: A qualitative interview study","author":"Kang","year":"2018","journal-title":"Res Social Adm Pharm."},{"key":"10.1016\/j.rcsop.2021.100029_bb0265","article-title":"\u201cThey talk to me like a person\u201d Experiences of people with opioid use disorder in an injectable opioid agonist treatment (iOAT) program: A qualitative interview study using interpretive description","author":"Jackson","year":"2021","journal-title":"Qeios"},{"issue":"1","key":"10.1016\/j.rcsop.2021.100029_bb0275","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/10826084.2019.1654514","article-title":"\u201cIt\u2019s took over this region\u201d: patient perspectives of prescription drug Abuse in Appalachia","volume":"55","author":"Mathis","year":"2020","journal-title":"Subst Use Misuse"},{"issue":"10","key":"10.1016\/j.rcsop.2021.100029_bb0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186458","article-title":"Is patient empowerment the key to promote adherence? A systematic review of the relationship between self-efficacy, health locus of control and medication adherence","volume":"12","author":"Nafradi","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.rcsop.2021.100029_bb0285","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.drugpo.2013.12.012","article-title":"Spatial accessibility of drug treatment facilities and the effects on locus of control, drug use, and service use among heroin-injecting Mexican American men","volume":"25","author":"Kao","year":"2014","journal-title":"Int J Drug Policy."}],"container-title":["Exploratory Research in Clinical and Social Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667276621000299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667276621000299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T08:29:41Z","timestamp":1757406581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667276621000299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":56,"alternative-id":["S2667276621000299"],"URL":"https:\/\/doi.org\/10.1016\/j.rcsop.2021.100029","relation":{},"ISSN":["2667-2766"],"issn-type":[{"value":"2667-2766","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic literature review of patient perspectives of barriers and facilitators to access, adherence, stigma, and persistence to treatment for substance use disorder","name":"articletitle","label":"Article Title"},{"value":"Exploratory Research in Clinical and Social Pharmacy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rcsop.2021.100029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100029"}}